Recall archive / FDA drug enforcement
UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323 — FDA record D-0166-2025
Reported ongoing
Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.
Source date Nov 14, 2024. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
What the record says
- Product
- UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323
- Reason
- cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.
- Classification
- Class II
- Recalling firm
- MXBBB
- Quantity
- 321 bottles
- Agency-reported status
- Ongoing
- Source record identifier
- D-0166-2025
What the recall classes mean. Classification is an agency assessment, not individual medical advice.
Lot and product identifiers
| Label field | Details supplied by the agency |
|---|---|
| Lot, code or applicability | Lot#: 24183, Exp 07/01/28 |
Match all identifying details in the current notice. A brand name alone is not enough.
Distribution
Product was sold via Amazon Marketplace.
No US distribution state could be established from this record. Check the official notice.
Dates in the source
- Report date
- Jan 1, 2025
- Recall initiation date
- Nov 14, 2024
- Center classification date
- Dec 26, 2024
FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.